Praluent's ODYSSEY Continues As It Reduces Apheresis Need

Adding Sanofi/ Regeneron's Praluent to existing treatment regimens can reduce or even eliminate the need for expensive and cumbersome apheresis in patients with heterozygous familial hypercholesterolemia (HeFH), top-line data from the first Phase III study in this setting show.